American journal of cancer research最新文献

{"title":"Development and validation of a prediction model for myelosuppression in lung cancer patients after platinum-based doublet chemotherapy: a multifactorial analysis approach.","authors":"Xueyan Li, Linyu Li, Lu Zhang","doi":"10.62347/TFUC2568","DOIUrl":"10.62347/TFUC2568","url":null,"abstract":"<p><strong>Objective: </strong>To develop an individualized prediction model for myelosuppression risk in lung cancer patients undergoing platinum-based doublet chemotherapy and validate its predictive efficacy.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 584 lung cancer patients who received platinum-based doublet chemotherapy at The Affiliated Hospital of Qingdao University between January 2016 and December 2020. Patients were randomly assigned to a training cohort (n=391) and a validation cohort (n=193). Myelosuppression occurred in 280 (71.6%) patients in the training cohort and 132 (68.4%) in the validation cohort. Univariate analysis and LASSO regression were used to identify independent risk factors for myelosuppression. Prediction models were developed using Support Vector Machine (SVM), Random Forest, Extreme Gradient Boosting (XGBoost), and Adaptive Boosting (Adaboost). Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and Decision Curve Analysis (DCA). The SHAP algorithm was employed to evaluate feature importance, and a nomogram was developed for individual risk prediction.</p><p><strong>Results: </strong>LASSO regression identified 10 independent risk factors for myelosuppression: age, body mass index (BMI), white blood cell count, neutrophil count, platelet count, total protein, gender, treatment regimen, targeted therapy, and first chemotherapy cycle. In the training cohort, the XGBoost model exhibited the best performance, with an area under the curve (AUC) of 0.855 (95% CI: 0.813-0.897), while the AUC in the validation cohort was 0.793. SHAP analysis identified white blood cell count, platelet count, neutrophil count, BMI, and age as the most influential predictors. The SHAP analysis based on the XGBoost model demonstrated substantial value.</p><p><strong>Conclusion: </strong>This study successfully developed an individualized prediction model for myelosuppression risk in lung cancer patients following platinum-based doublet chemotherapy, with the XGBoost model achieving high predictive accuracy and clinical utility. The model provides a valuable tool for guiding precision medicine.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"470-486"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microporous annealed particle hydrogels in cell culture, tissue regeneration, and emerging application in cancer immunotherapy.","authors":"Junjie Wang, Qin Zhang, Liwen Chen","doi":"10.62347/WRGW4430","DOIUrl":"10.62347/WRGW4430","url":null,"abstract":"<p><p>Microporous annealed particle (MAP) hydrogels consist of densely crosslinked and annealed hydrogel particles. Compared to common hydrogels, the inherent porosity within and among these hydrogel particles offers interconnected channels for substance exchange in addition to sufficient growth space for cells, thereby forming a three-dimensional culture system that highly mimics the in vivo microenvironment. Such characteristics enable MAP hydrogels to adapt to various requirements of biomedical applications, along with their excellent injectability and mechanical properties. This review initially provides a comprehensive summary of the fabrication methods and material types of MAP hydrogels, alongside an assessment of their mechanical properties and porosity. In vitro studies are evaluated based on the impact of MAP hydrogels on cellular behaviors, focusing on cell proliferation, differentiation, migration, activity, and phenotype. In vivo research highlights the promising applications of MAP hydrogels in tissue regeneration, as well as their innovative use in cancer immunotherapy. Current challenges and future research directions are outlined, underscoring the potential of MAP hydrogels to significantly improve clinical outcomes in cancer treatment and regenerative medicine.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"665-683"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patho-Net: enhancing breast cancer classification using deep learning and explainable artificial intelligence.","authors":"Kalappanaickenpatty Suriaprakasam Manojee, Athiappan Rajiv Kannan","doi":"10.62347/XKFN1793","DOIUrl":"10.62347/XKFN1793","url":null,"abstract":"<p><p>Breast cancer is a disorder affecting women globally, and hence an early and precise classification is the best possible treatment to increase the survival rate. However, the breast cancer classification faced difficulties in scalability, fixed-size input images, and overfitting on limited datasets. To tackle these issues, this work proposes a Patho-Net model for breast cancer classification that overcomes the problems of scalability in color normalization, integrates the Gated Recurrent Unit (GRU) network with the U-Net architecture to process images without the need for resizing and computational efficiency, and addresses the overfitting problems. The proposed model collects and normalizes histopathology images using automated reference image selection with the Reinhard method for color standardization. Also, the Enhanced Adaptive Non-Local Means (EANLM) filtering is utilized for noise removal to preserve image features. These preprocessed images undergo semantic segmentation to isolate specific parts of an image, followed by feature extraction using an Improved Gray Level Co-occurrence Matrix (I-GLCM) to reveal fine patterns and textures in images. These features serve as input into the classification U-Net model integrated with GRU networks to improve the model performance. Finally, the classification result is expanded, and XAI is used for clear visual explanations of the model's predictions. The proposed Patho-Net model, which uses the 100X BreakHis dataset, achieves an accuracy of 98.90% in the classification of breast cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"754-768"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric nasal septum pleomorphic adenoma: a case report.","authors":"Jialian Feng, Yatian Liu, Jianguo He, Xiao Jiao","doi":"10.62347/PNUH7125","DOIUrl":"10.62347/PNUH7125","url":null,"abstract":"<p><p>Pleomorphic adenoma (PA), the most common benign salivary gland tumor, is rarely found in the nasal cavity and paranasal sinuses, particularly in pediatric patients. This report presents a case of PA in the nasal septum of a 14-year-old girl who presented with unilateral epistaxis and progressive nasal obstruction. The tumor was excised from the left anterior nasal septum via endoscopic sinus surgery, and PA was confirmed through histopathological examination. This case emphasizes the importance of including PA in the differential diagnosis of pediatric sinonasal masses, despite its rarity, and underscores the necessity of meticulous surgical planning to prevent recurrence. Further studies are needed to better understand the long-term outcomes and optimal management strategies for this rare condition in children.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"661-664"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential benefits of combined treatment with Hsp90 inhibitor AUY922 and cisplatin for overcoming drug resistance in nasopharyngeal carcinoma.","authors":"William C Cho, Chi F Wong","doi":"10.62347/OSGO7209","DOIUrl":"10.62347/OSGO7209","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC) initially responds well to platinum-based therapy but often develops resistance. Combining therapies may offer a viable approach to address this resistance. Heat shock protein 90 (Hsp90) has shown promising anticancer activity in various cancer types. This study aimed to investigate the efficacy of an Hsp90 inhibitor, luminespib (AUY922), and evaluate the synergistic effect of combining AUY922 with cisplatin on two cisplatin-resistant human NPC cell lines. The response of cisplatin-resistant NPC cells to AUY922 and/or cisplatin was assessed through proliferation assay, cell cycle analysis, Annexin V apoptosis detection, Western blot analysis, <i>in vivo</i> investigation, and histological analysis. Our results indicated that AUY922/cisplatin combination significantly inhibited the proliferation of both non-resistant and resistant NPC cells. Moreover, Annexin V analysis indicated apoptosis when AUY922 was administered alone or in combination with cisplatin. Consistently, Western blot analysis revealed increased cleavage of PARP. Most importantly, the combination treatment demonstrated enhanced tumor growth inhibition in nude mice xenograft models, without notable adverse effects. These findings highlight the antiproliferative effects and anticancer activity of the AUY922/cisplatin combination in cisplatin-resistant NPC cells. The combination treatment of AUY922 and cisplatin holds promise as a strategy to overcome drug resistance in NPC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"533-545"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GDF15 promotes the resistance of epithelial ovarian cancer cells to gemcitabine via DHCR24-mediated cholesterol metabolism to elevate ABCB1 and ABCC1 levels in lipid rafts.","authors":"Linlin Guo, Yan He, Huang Xin","doi":"10.62347/KYIY8286","DOIUrl":"10.62347/KYIY8286","url":null,"abstract":"<p><p>Growth differentiation factor 15 (GDF15) is upregulated in most cases of epithelial ovarian cancer (EOC); however, its functions in EOC are not fully understood. In this study, we knocked down GDF15 in EOC cells before performing high-throughput sequencing to identify genes regulated by GDF15. GDF15 was overexpressed to determine its effect on the viability, migration, and response of EOC cells to gemcitabine, carboplatin, and paclitaxel. Reprogramming of glucose and cholesterol metabolism in EOC cells was evaluated based on oxygen consumption, lactic acid production, complex I activity, and free and esterified cholesterol levels. The activities of ATP-binding cassette (ABC)B1 and ABCC1 were assessed based on the expulsion efficiency of rhodamine 12. GDF15 overexpression promoted cell viability, migration, and resistance to gemcitabine. In addition, GDF15 induced glycolysis and increased cholesterol levels in EOC cells. Cholesterol metabolism regulated by GDF15 contributed to the resistance of EOC cells to gemcitabine by elevating ABCB1 and ABCC1 levels in lipid rafts. DHCR24 plays an important role in cholesterol synthesis. DHCR24 was identified as a downstream effector of GDF15, because knockdown of DHCR24, but not treatment with statins, suppressed the cancer-promoting effect of GDF15. Overall, GDF15 promoted the resistance of EOC cells to gemcitabine via DHCR24-mediated cholesterol metabolism to elevate ABCB1 and ABCC1 levels in lipid rafts. Therefore, GDF15 and DHCR24 are potential therapeutic targets for suppressing the growth of EOC cells and improving their sensitivity to gemcitabine.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"452-469"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Random survival forest model in patients with epithelial ovarian cancer: a study based on SEER database and single center data.","authors":"Luwei Wei, Guowei Chen, Huiying Liang, Li Li","doi":"10.62347/PLDH8547","DOIUrl":"10.62347/PLDH8547","url":null,"abstract":"<p><p>Clinical data of 1,780 patients with epithelial ovarian carcinoma (EOC) in the Surveillance, Epidemiology and End Results (SEER) database were retrospectively analyzed. A random survival forest model and a nomogram model were built based on the prognostic factors. The clinical data of 140 patients with EOC treated in Liuzhou Worker's Hospital were collected for the validation of the prognostic model. Age (≥75 years), histology grade (poor differentiation or undifferentiation), histologic types (clear cell carcinoma or carcinosarcoma), T stage (T2 or T3), M stage (M1), surgical conditions, and chemotherapy situation (without chemotherapy) were identified as independent risk factors. Based on these factors, a random forest survival prediction model was established. In the training set, the area under the curve (AUC) for the random forest survival prediction model in predicting 1-, 3- and 5-year survival were 0.848, 0.859 and 0.890, respectively. In the test set, the AUCs for 1-, 3- and 5-year survival were 0.992, 0.795 and 0.883, respectively. A nomogram prediction model was also established. In the training set, the AUCs for the nomogram prediction model for 1-, 3- and 5-year survival were 0.789, 0.803 and 0.838, respectively. In the test set, the AUCs for 1-, 3- and 5-year survival were 0.926, 0.748 and 0.836, respectively. The results indicated that the random forest survival model established in this study holds significant clinical value. Physicians can develop personalized follow-up strategies or treatment regimens for patients based on the predicted survival risk, potentially improving long-term outcomes.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"769-780"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for immunoresistance in advanced non-small cell lung cancer and the advantages of targeted therapy in improving prognosis.","authors":"Ping Yang, Shangxiang He, Linyin Fan, Ling Ye, Heng Weng","doi":"10.62347/FGAY1920","DOIUrl":"10.62347/FGAY1920","url":null,"abstract":"<p><strong>Objectives: </strong>The advent of immunotherapy has transformed the therapeutic landscape for advanced non-small cell lung cancer (NSCLC); nonetheless, the emergence of resistance to immunotherapy poses a considerable obstacle. Our research sought to identify factors contributing to immunotherapy resistance and to assess the effectiveness of subsequent treatments in patients with advanced NSCLC who have been exposed to immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>This retrospective study analyzed data from 232 individuals with advanced NSCLC who were treated with ICIs during January 2020 to December 2023. Based on their response to ICIs, these patients were classified into two groups: immunoresistance group (IM group) and non-immunoresistance group (NIM group). Data collected included demographics, clinical parameters, cytokine profiles, tumor mutational burden (TMB), PD-L1 expression, overall survival (OS), progression-free survival (PFS), and adverse events. The association between risk factors and immunoresistance were assessed, and second-line treatment outcomes were evaluated.</p><p><strong>Results: </strong>Key risk factors for immunoresistance included lower TMB, higher levels of interleukin-10 (IL-10), and PD-L1 expression ≥ 50%. TMB was inversely correlated with immunoresistance (rho = -0.838, <i>P</i> < 0.001). In multivariate analysis, IL-10 remained a significant risk factor (OR = 33.654, <i>P</i> = 0.021), whereas TMB was protective (OR = 0.786, <i>P</i> < 0.001). Second-line targeted therapy significantly improved OS (8.72 ± 2.02 months) and PFS (5.37 ± 2.15 months) compared to chemotherapy (OS: 7.93 ± 2.13 months; PFS: 4.86 ± 1.68 months) (<i>P</i> < 0.05). The targeted therapy group experienced distinct side effects, notably increased hypertension and hand-foot syndrome, while chemotherapy group had higher rates of fatigue (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Immunoresistance in advanced NSCLC is influenced by IL-10, TMB, and PD-L1 expression. Targeted therapies offer superior outcomes than chemotherapy, though side effect management remains crucial.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"573-586"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of trilaciclib for preventing myelosuppression in small cell lung cancer patients treated with etoposide, carboplatin, and atezolizumab.","authors":"Xiaoya Hu, Mingpu Liu, Yuanli Wu, Weiying Zhou, Hongmei Wang","doi":"10.62347/SNXD3155","DOIUrl":"10.62347/SNXD3155","url":null,"abstract":"<p><p>This study evaluated the economic value of administering trilaciclib to prevent myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving etoposide, carboplatin, and atezolizumab (E/P/A) from both the Chinese and the United States (US) perspectives. A decision tree model was constructed to estimate and compare costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). One-way and probabilistic sensitivity analyses were conducted to assess the robustness and uncertainty of the economic analysis. The base case analysis indicated that from the perspective of US payers, trilaciclib was cost-saving at the WTP threshold of $241,230.00, with an incremental cost of $-12,626.08, an INMB of $16,788.02, and an INHB of 0.07 QALYs. Conversely, from the perspective of Chinese payers, the use of trilaciclib was not economical at the WTP threshold of $35,817.44, with an ICER of $691,541.63/QALY, an INMB of -$8,765.52, and an INHB of -0.24 QALYs. Sensitivity analysis confirmed the stability of these results. Probabilistic sensitivity analysis indicated that, from the Chinese payers' perspective, trilaciclib treatment was not economical, with a probability of 100%. In contrast, from the US payers' perspective, it was economical, with a probability of 90.05%. Given the limited clinical data available for trilaciclib in the Chinese population, the cost-effectiveness of trilaciclib may improve with the inclusion of new data or changes in health insurance policies.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"559-572"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma exosomal miR-150-3p, <i>NMT2</i>, and <i>PRDM1</i> as predictive biomarkers of acute tumor response in patients with cervical cancer undergoing chemoradiotherapy.","authors":"Oyeon Cho","doi":"10.62347/SPQY5709","DOIUrl":"10.62347/SPQY5709","url":null,"abstract":"<p><p>Locally advanced cervical cancer (LACC) is primarily treated with weekly cisplatin-based concurrent chemoradiotherapy (CCRT); however, predicting acute tumor response remains challenging. This study aimed to identify plasma exosomal microRNAs (miRNAs) and messenger RNAs (mRNAs) that could predict rapid tumor regression in patients with LACC undergoing CCRT. Overall, 41 patients with stage IB-IVB cervical cancer were included. All patients received CCRT, and plasma exosomal RNA samples were collected before treatment and 2 weeks after radiation therapy (RT). Acute tumor response (AR) was defined as the regression rate of tumor volume (TV) (cm³) measured at the fourth week of treatment compared with the initial TV (iTV). The log₂ fold change of miRNA and mRNA was calculated by comparing RNA read counts before and after the second week of CCRT for each patient. A correlation matrix identified RNAs associated with AR. The selected RNAs were validated through linear regression and Wilcoxon rank-sum tests. Leave-one-out cross-validation was performed in subgroups based on iTV. miR-150-3p, <i>NMT2</i>, and <i>PRDM1</i> were identified as key predictors of AR, demonstrating significant associations with immune-mediated tumor responses. A decrease in post-RT levels of these RNAs was significantly associated with poor AR, particularly in patients with large iTVs. The predictive model combining miR-150-3p, <i>NMT2</i>, and <i>PRDM1</i> showed strong correlation with AR (R² = 0.831, <i>P</i> < 0.0001) in the test dataset and was validated in an independent cohort (R² = 0.496, <i>P</i> = 0.006). Cross-validation indicated the robustness of these biomarkers in predicting AR across varying TVs. These findings highlight the potential of plasma exosomal miR-150-3p, <i>NMT2</i>, and <i>PRDM1</i> are promising biomarkers for predicting AR in patients with LACC undergoing CCRT. These findings could facilitate personalized RT strategies and improve patient outcomes. Further multicenter studies are warranted to validate these biomarkers in larger, diverse cohorts.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"546-558"},"PeriodicalIF":3.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}